Showing 1 - 8 results of 8 for search 'Shailender Bhatia', query time: 0.02s Refine Results
  1. 1
    Programmed cell death 1 blockade in the setting of severe ocular sarcoidosis: Cancer immunotherapy in a patient with autoimmunity

    Programmed cell death 1 blockade in the setting of severe ocular sarcoidosis: Cancer immunotherapy in a patient with autoimmunity by Charlotte Read, MD, PhD, Shailender Bhatia, MD, Mariam Totonchy, MD

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy

    Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy by Shailender Bhatia, Paul Nghiem, Tomoko Akaike, Song Y Park, Peter H Goff, Austin J Jabbour

    Published 2024-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Concurrent treatment with transarterial immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma

    Concurrent treatment with transarterial immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uv... by Natalie J. Miller, Sharon W. Kwan, Jacob B. Leary, Daniel S. Hippe, William McCamy, Joshua R. Veatch, Evan T. Hall, Wayne L. Monsky, Shailender Bhatia

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses

    Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses by Shailender Bhatia, Paul Nghiem, Rima Kulikauskas, Candice Church, David M Koelle, Lisa Tachiki, Kimberly Smythe, Thomas Pulliam, Shira Tabachnick-Cherny, Saumya Jani, Peter H Goff, Rashmi Bhakuni, Brandon W Seaton

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)

    Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201) by Federica Morano, Celeste Lebbe, Mark Cornfeld, Shailender Bhatia, Melissa Burgess, Giovanni Grignani, Piotr Rutkowski, Francesca Spada, Michele Guida, Chuan Tian, Caroline Gaudy-Marqueste, Roberta Depenni, Henri Montaudié, Jennifer Pulini, Francesco Spagnolo, Cecilia C S Yeung

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma

    Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma by Jamie S. K. Takayesu, Upendra Parvathaneni, George E. Laramore, Neil Panjwani, Jennifer Sillings, Neal D. Futran, Ian M. Humphreys, Aria Jafari, Waleed M. Abuzeid, Brittany Barber, Emily Marchiano, Sylvia M. Lee, John A. Thompson, Evan Hall, Shailender Bhatia, Cristina P. Rodriguez, Jay J. Liao

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade

    Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade by Shailender Bhatia, Daniel S Hippe, Paul T Nghiem, Candice Church, Tomoko Akaike, Kristina Lachance, Lisa Tachiki, Thomas Pulliam, Song Y Park, Coley Doolittle-Amieva, Lisa Zaba, Nora A Alexander, Emily Gong, Lauren Zawacki, Allison J Remington, Yasman Moshiri, Alex Fu, Emily Huynh, Nikhil Harikrishnan, Marika Bierma

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

    Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors by Douglas E Feltner, Adil Daud, Brent A Hanks, Shailender Bhatia, Michael K Wong, Sunandana Chandra, Trisha M Wise-Draper, Philip A Friedlander, Melissa A Burgess, Glenn J Hanna, C Lance Cowey, George Ansstas, Ciara M Kelly, Mohammed M Milhem, Cesar A Perez, Ryan M Weight, Alice S Bexon, Douglas E Laux, Theresa M Medina, Steven J O’Day, Timothy S Kristedja, Weston L Daniel, Scott Mix, Laurel Sindelar, Martin F Bexon, Robert E Michel

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: